On February 19, 2025, Neurogen Biomarking announced an exclusive global agreement with Quanterix Corporation. This agreement grants Neurogen Biomarking exclusive rights to commercialize Quanterix's ultrasensitive technology for direct-to-consumer testing in the United States, Europe, and pan-Asia.
The partnership focuses on using Quanterix's antibody technology to measure phosphorylated tau 217 (P-tau217), a specific blood biomarker for early detection of dementia and Mild Cognitive Impairment (MCI) due to Alzheimer’s disease. Neurogen Biomarking's platform will include an easy-to-use at-home blood biomarker collection test.
Neurogen Biomarking's CEO, Dr. Rany Aburashed, stated that this collaboration brings them closer to shifting the standard of care for Alzheimer's detection by providing easier access to clinically validated blood biomarker technology. The platform is expected to be commercially available in early Q2 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.